CVS Health Corporation $CVS Stock Holdings Reduced by Aaron Wealth Advisors LLC

Aaron Wealth Advisors LLC cut its position in shares of CVS Health Corporation (NYSE:CVS) by 31.2% in the first quarter, Holdings Channel reports. The firm owned 25,018 shares of the pharmacy operator’s stock after selling 11,328 shares during the period. Aaron Wealth Advisors LLC’s holdings in CVS Health were worth $1,797,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Caitong International Asset Management Co. Ltd increased its holdings in CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after buying an additional 281 shares during the last quarter. Swiss RE Ltd. acquired a new stake in CVS Health in the fourth quarter valued at approximately $26,000. Sankala Group LLC bought a new stake in CVS Health in the fourth quarter worth approximately $28,000. Mcguire Capital Advisors Inc. acquired a new position in shares of CVS Health during the 4th quarter worth $28,000. Finally, Ares Financial Consulting LLC bought a new position in shares of CVS Health during the 4th quarter valued at $29,000. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Trading Up 2.6%

Shares of NYSE:CVS opened at $104.50 on Friday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The stock’s 50-day moving average is $91.23 and its 200-day moving average is $82.24. The company has a market cap of $133.33 billion, a P/E ratio of 46.03, a P/E/G ratio of 1.00 and a beta of 0.62. CVS Health Corporation has a 52-week low of $58.50 and a 52-week high of $104.94.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.36. The business had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities research analysts predict that CVS Health Corporation will post 7.44 earnings per share for the current year.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS is expanding its direct-to-consumer GLP-1 weight-loss program, which could support new growth and improve margins if demand continues. CVS expands direct-to-consumer GLP-1 weight-loss program
• Positive Sentiment: Analysts/valuation updates have nudged CVS’s implied fair value higher, reflecting improving views on GLP-1 engagement, margins, and earnings resilience. CVS Health (CVS) Stock Sees Modest Fair Value Lift As GLP 1 And Margins Help
• Positive Sentiment: CVS Health Foundation announced $2 million in combined grants to Hartford- and Rhode Island-area nonprofits, reinforcing community ties and its local health access message. CVS Health Foundation invests $1 million in Hartford nonprofits tackling community health needs
• Positive Sentiment: CVS won a whistleblower drug lawsuit, removing a potential legal overhang. CVS Health Beats Whistleblower’s Worthless Services Drug Suit

Insider Buying and Selling

In other news, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the sale, the director directly owned 6,213,261 shares of the company’s stock, valued at approximately $586,842,501.45. This represents a 24.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares in the company, valued at approximately $907,714.14. The trade was a 87.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 3,441,551 shares of company stock valued at $323,703,977. Corporate insiders own 0.85% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on CVS shares. Sanford C. Bernstein lifted their price objective on shares of CVS Health from $94.00 to $106.00 and gave the company an “outperform” rating in a research note on Tuesday, May 12th. Wall Street Zen upgraded CVS Health from a “hold” rating to a “buy” rating in a report on Sunday, June 21st. Barclays boosted their price target on CVS Health from $101.00 to $106.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 26th. Bank of America increased their price objective on CVS Health from $100.00 to $110.00 and gave the company a “buy” rating in a report on Monday. Finally, DA Davidson raised their price objective on CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Twenty-two analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, CVS Health presently has an average rating of “Moderate Buy” and a consensus target price of $101.28.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.